Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma — TARMAC

Mantle Cell Lymphoma Recurrent Clinical Trial

Official title:
A Phase II, Open-Label, Single Arm Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma

Status Active, not recruiting

Clinical Trial Summary

This is an open label, multi-center, single-arm, phase II study investigating the efficacy and safety of the combination of ibrutinib and Tisagenlecleucel in twenty patients with relapsed or refractory Mantle Cell Lymphoma (MCL) or who had sub-optimal response to standard therapy in the presence of TP53 mutation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04234061
Study type	Interventional
Source	Peter MacCallum Cancer Centre, Australia
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	April 7, 2020
Completion date	September 1, 2030

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05645744` - Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
Recruiting	`NCT05360238` - Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL	Phase 1/Phase 2
Recruiting	`NCT02086591` - A Phase II Study of Doxycycline in Relapsed NHL	Phase 2
Recruiting	`NCT01322776` - Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma	Phase 1/Phase 2